RGL-305+ Lymphoma + Exploratory Clinical Study
NCT07006012
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Interventions
DRUG:
RGL-305
Sponsor
Fudan University